Alzheimer’s Experts: Lecanemab Is A Win, But Also Just The Beginning

CTAD Panelists Cheer Eisai/Biogen Data, Note Challenges Ahead

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.